Click a link below to view the mailing archive as if it had been sent to you.
| 2026-03-31 12:15 | | Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play and more... |
| 2026-03-30 12:15 | | Takeda begins US layoffs as part of massive $1.3B restructuring and more... |
| 2026-03-30 00:15 | | ACC26: Merck & Co. moving Winrevair into Phase III testing for uncommon heart condition and more... |
| 2026-03-27 12:15 | | Novartis pens $2B deal for allergy biotech with potential Xolair successor and more... |
| 2026-03-27 00:15 | | Kodiak Sciences shares surge after eye drug succeeds in late-stage study and more... |
| 2026-03-26 12:15 | | Novo Nordisk's strategic U.S. expansion with new board appointment and more... |
| 2026-03-26 00:15 | | Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape and more... |
| 2026-03-25 12:15 | | Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug and more... |
| 2026-03-25 00:15 | | House panel warns China controls key parts of US drug supply and more... |
| 2026-03-24 12:15 | | Large pharma companies reduced head counts by more than 22K in 2025 as $300B patent cliff looms and more... |
| 2026-03-24 00:15 | | Gilead Sciences to acquire Ouro Medicines to advance first in class T cell engager program for autoimmune diseases |
| 2026-03-23 12:15 | | Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D and more... |
| 2026-03-23 00:15 | | EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug and more... |
| 2026-03-21 00:15 | | 🎧 CP Midday Brief: Novartis Spends Billions As Novo Defends Wegovy |
| 2026-03-20 12:15 | | Novartis buys breast cancer drug for $2b to keep up with myriad rivals and more... |
| 2026-03-20 00:15 | | Novo uses FDA voucher to win speedy approval of higher-dose Wegovy and more... |
| 2026-03-19 12:15 | | Lilly builds differentiated profile for triple-G agonist with late-stage diabetes data and more... |
| 2026-03-19 00:15 | | 🎧 CP Midday Brief: Big Pharma Lawsuits and Patent Cliffs |
| 2026-03-18 12:15 | | Big drugmakers must face us overcharge claims on medications for low-income patients and more... |
| 2026-03-17 12:15 | | Pfizer's hotly tipped breast cancer prospect delivers phase 2 win and more... |
| 2026-03-17 00:15 | | Structure Climbs on ‘Highly Competitive’ Profile for Weight Loss Pill and more... |
| 2026-03-16 12:15 | | Meds from Amgen, GSK now offered through TrumpRx DTC platform and more... |
| 2026-03-13 12:15 | | Eliquis proves safer than Xarelto for patients with deep blood clots and more... |
| 2026-03-13 00:15 | | Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out and more... |
| 2026-03-12 00:15 | | Biogen builds case for Spinraza successor with fresh data and more... |
| 2026-03-11 12:15 | | UCB's Bimzelx gets psoriatic arthritis uplift after topping AbbVie's Skyrizi in study and more... |
| 2026-03-11 00:15 | | Stryker Tackles Hospital Fragmentation with AI-Powered SmartHospital Platform and more... |
| 2026-03-10 12:15 | | FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial and more... |
| 2026-03-10 00:15 | | Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs and more... |
| 2026-03-09 12:15 | | Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit and more... |
| 2026-03-06 12:15 | | FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap and more... |
| 2026-03-06 00:15 | | Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal and more... |
| 2026-03-05 12:15 | | Bayer’s Q4 Cuts Put YOY Drop at About 4,700 Employees and more... |
| 2026-03-05 00:15 | | FDA answers Vanda's yearslong call for public hearing on unsuccessful jet lag approval bid and more... |
| 2026-03-04 12:15 | | Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval and more... |
| 2026-03-03 12:15 | | How North Carolina attracted Amgen and Roche to become a next-gen obesity drug production hotspot and more... |
| 2026-03-03 00:15 | | Bysanti FDA Approval for Bipolar I and Schizophrenia Marks Vanda’s Second Win in Two Months and more... |
| 2026-03-02 12:15 | | Merck's Welireg combos deliver 1-2 punch to kidney cancer and more... |
